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Abstract
Background: Patients with advanced haematological malignancies suffer from a very high symptom burden and
psychological, spiritual, social and physical symptoms comparable with patients with metastatic non-haematological
malignancy. Referral to palliative care services for these patients remains limited or often confined to the last days
of life. We developed a palliative care intervention (PCI) integrated with standard haematological care. The aim of
the study was focussed on exploring the feasibility of the intervention by patients, professionals and caregivers and
on assessing its preliminary efficacy.
Methods/design.
This is a mixed-methods phase 2 trial.
The Specialist Palliative Care Team (SPCT) will follow each patient on a monthly basis in the outpatient clinic or will
provide consultations during any hospital admission. SPCT and haematologists will discuss active patient issues to
assure a team approach to the patient’s care.
This quantitative study is a monocentric parallel-group superiority trial with balanced randomisation comparing the
experimental PCI plus haematological standard care versus haematological standard care alone.
The primary endpoint will calculate on adherence to the planned PCI, measured as the percentage of patients
randomised to the experimental arm who attend all the planned palliative care visits in the 24 weeks after
randomisation.
The qualitative study follows the methodological indications of concurrent nested design and was aimed at exploring
the acceptability of the PCI from the point of view of patients, caregivers and physicians.
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Discussion: In this trial, we will test the feasibility of an integrated palliative care approach starting when the
haematologist decides to propose the last active treatment to the patient, according to his/her clinical
judgement. We decided to test this criterion because it is able to intercept a wide range of patients’needs.
The feasibility of this approach requires that we enrol at least 60 patients and that more than 50% of them
be followed by the palliative care team for at least 24 weeks.
The trial will include integrated qualitative data analysis; to give essential information on feasibility and
acceptability.
Trial registration: ClinicalTrials.gov: NCT03743480 (November 16, 2018).
Background
The most recent World Health Organization (WHO)
definition of palliative care advocates that palliative care
principles “…should be applied as early as possible in the
course of any chronic, ultimately fatal illness” [1]. The
difference to the previous WHO vision is substantial [2],
as the earlier definition recommended palliative care to
patients not responsive to curative therapy, limiting its
role to the last period of life.
Evidence about the effectiveness of an early integration
of palliative care has emerged in recent years for patients
with solid tumours. A recent Cochrane systematic re-
view identified seven eligible randomised clinical trials
(RCTs) comparing the effects of early palliative care in-
terventions versus standard cancer care on quality of life,
depression, symptom intensity, and survival among ad-
vancer cancer patients [3]. The results of this review
suggested that early palliative care had significantly
beneficial effects on quality of life, with a standardised
mean difference (SMD) of 0.27 (95% confidence interval
(CI) 0.15 to 0.38), and on symptom intensity, with a
SMD of − 0.23 (95% CI − 0.35 to − 0.10), among patients
with advanced cancer. Effects on mortality and depres-
sion remained uncertain [4]. The results of qualitative
studies performed in different countries suggested that
the early integration of specialised palliative care is well
accepted by patients, relatives and, to a lesser extent, on-
cologists [5–8].
Patients with advanced haematological malignancies
suffer from a very high symptom burden and psycho-
logical, spiritual, social and physical symptoms compar-
able with patients with metastatic non-haematological
malignancy [9–11]. During the last 30 days of life, haem-
atological patients are more frequently admitted to hos-
pital settings, emergency departments and high-care
wards and receive more aggressive treatments and more
chemotherapy or biologically active treatments than pa-
tients with advanced solid tumours [12].
Conversely, referral to palliative care services for
haematologic patients remains limited or often confined
to the last days of life [13, 14]. Haematologic specialists
show resistance to involving a palliative care service
because of the perceived contrast between ongoing ac-
tive treatments and palliative care, the latter being iden-
tified as terminal care [15].
In agreement with the new WHO vision [1], the evi-
dence from studies performed in patients with solid tu-
mours and haematologic patients’ symptom burden
suggests that an earlier and integrated provision of spe-
cialised palliative care has the potential to improve their
quality of life and reduce resource consumption through
effective management of psychological and physical
symptoms, appropriate relationships, effective communi-
cation and support in decision-making.
The call for an effective model of assistance integrating
specialised palliative care and haematologic services is
strong [16], although there is no agreement about what
the best approach is. To some authors, palliative care
should be integrated earlier in the trajectory of the ad-
vanced disease [17, 18], while others suggest an early in-
tegration according to patients’ needs [19, 20] or when
requested by the haematologist [21]. In some centres, in-
tegration of palliative care is assessed for patients under-
going stem cell transplantation [22].
A major challenge in designing a palliative care inter-
vention that is early integrated with onco-haematological
care is identifying the best timing for starting an inte-
grated intervention.
The evidence of the effectiveness of an early integra-
tion of palliative care with onco-haematological care is
poor and is based on few observational studies [10, 11,
23–26]. Only one randomised clinical trial assessed the
effectiveness of a palliative care intervention (PCI) in pa-
tients hospitalised for haematopoietic stem cell trans-
plantation [27]. The results showed a smaller decrease in
quality of life for patients randomised to receive PCI 2
weeks after transplantation.
Following the WHO vision, we developed a PCI inte-
grated with standard haematological care. This pilot study
was primarily focused on assessing the feasibility of the
PC intervention. Secondary aims include exploring its ac-
ceptability by patients, professionals and caregivers and
collecting preliminary information on its effectiveness,
which will be potentially useful for designing a
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randomised phase 3 trial. In this article, we describe the
protocol of the study.
Methods
Trial design
According to the Medical Research Council framework
for complex interventions [28, 29], this is a mixed-
methods phase 2 trial on early integration of palliative
care in patients with advanced haematological
malignancies.
This quantitative study is a monocentric parallel-group su-
periority trial with balanced randomisation (1:1) comparing
the experimental PCI plus haematological standard care ver-
sus haematological standard care alone (control arm).
The qualitative study follows the methodological indi-
cations of concurrent nested design [30], as both qualita-
tive and quantitative data are collected during the same
stage. The qualitative study will deepen the perceptions
of patients, family members and physicians involved in
the early integrated PCI.
Aims
Primary aim
The primary aim is to determine whether a specialised
PCI integrated with standard haematological care is feas-
ible in terms of adherence to the planned PCI.
Secondary aims
Quantitative secondary aims are to obtain Patient Re-
ported Outcomes Measures (PROMS) estimates to as-
sess the potential effectiveness of the intervention and to
inform the sample size calculations for a future large-
scale trial. More specifically, secondary aims include the
following assessments in the 24 weeks after enrolment:
• compliance with the assessment of quality of life;
• the main dimensions of quality of life measured with
the Palliative Care Outcome Scale questionnaire
(POS);
• the severity of physical and psychological symptoms
measured with the Edmonton Symptom Assessment
Scale questionnaire (ESAS);
• The severity of symptoms of anxiety and depression
measured with the Hospital Anxiety and Depression
Scale questionnaire (HADS);
• the functional status of the patient measured with
the Eastern Cooperative Oncology Group scale
(ECOG Performance Status).
Qualitative secondary aims are to explore the accept-
ability, perceived benefits and concerns, and strengths
and weaknesses of the PCI from the point of view of
interviewed patients, caregivers and physicians.
Eligibility criteria
Inclusion criteria
 histologically or cytologically confirmed incurable
haematological malignancy;
 age 18 years or more.
 life expectancy more than 1 month, according the
clinical judgement of both the haematologist and the
palliative care physician;
 The patient will start the last potentially active
treatment (chemotherapy or immunotherapy) as
established by the haematological team. Another
active treatment could follow this treatment
according to evidenced best practice and/or the
development of novel haematologic therapy.
Agreement on the new treatment between
referenced physicians is guaranteed.
 performance status of 0–3, according to the Eastern
Cooperative Oncology Group (ECOG);
 ability to understand, read and fill in questionnaires
in Italian;
 signed the written informed consent form.
Exclusion criteria
 patient without a caregiver;
 any physical, psychological or psychiatric condition
that, in the opinion of the clinical team, makes
participation to the study not appropriate.
Setting
Participants will be recruited from the Haematology De-
partment of the Arcispedale Santa Maria Nuova of Reg-
gio Emilia, Italy.
The Haematology division is located in the Santa Maria
Nuova hospital, Centro Onco Ematologico of Reggio Emi-
lia. It includes inpatient and outpatient services. The in-
patient service consists of 16 beds, 6 of which are used for
bone marrow transplantation (low microbial charge). The
outpatient service consists of 4 rooms with a total of 6
beds and 3 armchairs and 10 rooms for medical examina-
tions. Medical staff is made up of 14 haematologists orga-
nised by main area of haematology: inpatient and
transplant, lymphomas, myeloproliferative disorders, and
acute leukaemia. During 2018, there were 272 hospital ad-
missions and 39,479 ambulatory visits. The unit is certified
by Jaice for bone marrow transplantation (autologous and
allogenic) and is also certified for phase I trials.
The PCI is provided by the hospital Palliative Care Unit
(PCU), integrated for the care of patients and relatives
with severe psychological suffering with the hospital
Psycho-Oncology Unit. The PCU can be classified as a
specialised hospital-based unit with no beds [31]. At
present, it includes three senior physicians (one in
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advanced palliative care training) and two advance prac-
tice nurses, with a remit of specialist consultations in
wards and in a clinic for advanced outpatients and their
relatives.
Screening and informed consent
All study procedures are described in Fig. 1.
Haematologists and palliative care physicians identify
potentially eligible patients during weekly case discus-
sions in the Haematology Department.
We will register all potentially eligible patients and
reasons for no accruement, patients who were asked to
participate in the study, and patients who did not agree
to participate.
A haematologist will give to each eligible patient a de-
scription of the study and will ask them to participate in
the study.
Patients who agree to participate in the trial will be
asked to sign the written informed consent.
To achieve adequate patient enrolment and reach the
target sample size, the enrolment rate will be constantly
Fig. 1 Flow chart EPC-EMA 1
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monitored. To this aim, contacts with physicians will
take place on a weekly basis.
Randomisation
All patients who agree to participate in the study will be
randomly assigned to either the experimental or the
control group (1:1 ratio) according to a computer-
generated randomisation list created using permuted
blocks of random (undisclosed) sizes and stratified by
site (if other centres will join patient recruitment).
The allocation sequence will be generated by the Infra-
struttura Ricerca e Statistica (I-RS) of the Azienda USL-
IRCCS. Investigators involved in patient recruitment will
call by telephone the central randomisation centre (I-
RS), which will assign the patient a unique code and
communicate the arm of allocation. The randomisation
code will not be released before patient enrolment to en-
sure allocation concealment.
Endpoints
Primary endpoint
• Adherence to the planned PCI, measured as the per-
centage of patients randomised to the experimental arm
who attend all the planned palliative care visits in the 24
weeks after randomisation.
Secondary endpoints
 Compliance with the assessment of quality of life for
each questionnaire (POS, ESAS and HADS) at the
six planned times;
 Assessment of quality of life measured with the
Palliative Care Outcome Scale questionnaire (POS);
 The severity of physical and psychological symptoms
measured with the Edmonton Symptom Assessment
Scale questionnaire (ESAS);
 The severity of symptoms of anxiety and depression
measured with the Hospital Anxiety and Depression
Scale questionnaire (HADS);
 The functional status of the patient measured with
the Eastern Cooperative Oncology Group scale
(ECOG Performance Status).
All questionnaires will be proposed to patients (con-
trol/experimental arm) for self-assessment by two
trained researchers at the following time points: immedi-
ately after giving consent (t0), 4 weeks (± 7 days) after t0
(t1), 8 weeks (± 7 days) after t0 (t2), 12 weeks (± 7 days)
after t0 (t3), 16 weeks (± 7 days) after t0 (t4), 20 weeks (±
7 days) after t0 (t5) and 24 weeks (± 7 days) after t0 (t6).
Self-assessment will be the standard procedure. If this
is not possible, patients will be assisted by a research
physician. Assessment by other professionals or care-
givers is not allowed.
Baseline evaluation (t0) will be carried out in hospital.
To reduce deviation from the protocol and the dropout
rate, evaluations t1-t6 could be performed in hospital or
at the patient’s home, depending on the patient’s
preferences.
Four questionnaires will be used in this study:
 Palliative Care Outcome Scale (POS – version 2) in
its Italian-validated version [32]. POS is a widely
used questionnaire with a brief outcome measure. It
is commonly used in patients with advanced illnesses
in different settings: inpatient, outpatient, and com-
munity. POS comprises 10 items, including physical
and psychological symptoms, spiritual and emotional
dimensions, communication with patients and fam-
ilies, and practical concerns related to disease stage.
Each of the 10 items is scored with a Likert scale
ranging from 0 to 4. POS also includes an open op-
tional question to list the patient’s main concerns.
 The Edmonton Symptom Assessment Scale (ESAS)
in its Italian-validated version [33]. ESAS asks re-
spondents to rate the severity of 10 common symp-
toms (pain, fatigue, nausea, depression, anxiety,
drowsiness, shortness of breath, appetite, sleep, and
feeling of well-being) during the previous 24 h. It has
been found to be valid and reliable in cancer
populations.
 The Hospital Anxiety and Depression Scale (HADS)
in its Italian-validated version [34]. HADS is a self-
assessed 14-item questionnaire that has been tested
in cancer patients. It has two 7-item subscales asses-
sing depression and anxiety in the preceding week.
The scale is considered appropriate for cancer pa-
tients because of the lack of items regarding somatic
symptoms, which can confound the identification of
psychiatric issues. The format consists of four re-
sponses (range 0 to 3) that quantify the degree to
which an emotion is experienced by the patient. The
score on each subscale ranges from 0 to 21, and a
score greater than 11 is consistent with definitive de-
pression or anxiety. A score of less than 7 is normal,
and a score of 8–10 is considered borderline for de-
pression and anxiety.
 The Eastern Cooperative Oncology Group (ECOG)
Performance Status [35], a widely used scale to
evaluate and measure the functional status of a patient.
Data collection and management
We will collect Information on the use of health care
services including referral to hospice, hospital admis-
sions,emergengy department visits and the date and
place of death. In particular we will collect frequency
and date of palliative care visits in each arm, type, setting
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and timing of all chemotherapy, number of hospitaliza-
tions, emergency visits and use of hospice services.
Data will be collected on an electronic Case Report
File (eCRF) management system (Smarty Ver.3.85– Sinfo
S.R.L), validated and handled in accordance to local and
European regulatory requirements.
The qualitative assessment
A consecutive series of six patients enrolled in the ex-
perimental arm who attend at least three visits in the PC
outpatient clinic and their family members will be asked
to participate in the qualitative assessment. This assess-
ment will also be proposed to a sample of six physicians
involved in the care of recruited patients, selected
among those who follow the highest numbers of pa-
tients. Patients, family members, and physicians who
agree to participate in the qualitative study will be asked
to sign the specific written informed consent for the
interview and to give explicit permission to be audio-
recorded.
Information will be gathered through individual semi-
structured interviews [36]. The prompts are defined in
advance and listed in three topic guides [37] whose re-
sponsibility is up to a team member, expert in qualitative
evaluation in palliative care (Table 1). Researchers will
explore the acceptability of the intervention giving the
opportunity to the receivers (patients and family
members) and the haematologists, involved in early inte-
grated palliative care, to tell their experience. Given the
intervention’s characteristics discussed below, while the
semi-structured interviews administered to patients and
family members will focus on perceived benefits and
concerns of the early PC intervention, the physicians’ in-
terviews will address the strengths and weaknesses of
the intervention with reference to the respondents’ views
on patient and family caregiver experience.
Anonymity and non-traceability criteria will be duly
presented to all interviewees. The interviewers will be
two researchers with expertise in palliative care and
basic knowledge of the intervention but who will not be
involved in its implementation.
Training of all researchers involved in the study will
be carried out before the enrolment of any patient to
guarantee the study integrity.
The intervention offer
Haematologists will propose that a patient participate in
a study that will include early PC intervention integrated
with standard haematological care. To standardise the
proposal, a wording will be suggested to all the haema-
tologists as requested in a previous focus group between
haematologists and palliative care professionals in which
haematologists addressed the difficulty of using words
such as palliative care or palliative care intervention
Table 1 Semi-structure interview topic guides with prompts
Topic Patients Family members Physicians
Early
integration of
PC
Could you please tell me what you thought
when the haematologist proposed you this
intervention?
Did you talk with anyone about it? How did
you experience it?
Could you please tell me what you
thought when the haematologist
proposed to your loved-one this
intervention?
Could you please tell me what you
thought about this intervention when
you heard about it?
Relationship Could you please tell me how is the
relationship with the hematologist? And what
about the palliativist?
Could you please tell me what is your
relationship with the hematologist? And
what about the palliativist?
How is your relationship as a physician
with the patients in the study?
Perceived
benefits/
strengths
Regarding your participation in this study,
could you please tell me what was good for
you? What can be the positive aspects of
this?
Regarding the participation in this study,
could you please tell me what was good
for you as caregiver? What can be the
positive aspects of this?
Regarding this study, could you please tell
me what the strengths of this
intervention are, according to your
opinion? If it impacted on your usual job,
how did it do?
Concerns/
weaknesses
Could you please tell me if you had concerns
about the intervention? What can be the
negative aspects of this?
Could you please tell me if you had
concerns about the intervention? What
can be the negative aspects of this?
Regarding this study, could you please tell
me what the weaknesses of this
intervention are?
Feelings In general, could you please tell me how you
felt during this study? Is there any example
you would like to share?
What about the support you received?
In general, could you please tell me how
you felt during this study? Is there any
example you would like to share?
What about the support you received?
And what about the support your loved-
one received?
As professional caregiver, could you
please tell me how you felt? How did you
experience the relationship with the
palliativist? And with the patients and
their family members?
Decision-
making and
advance care
planning
Could you please tell me how you made the
decisions this intervention required? What did
you think when you have been involved in
the advance care planning?
Could you please tell me how the
decision-making process went? What did
you think when you have been involved
in the advance care planning of your
loved-one?
Could you please tell me your opinion
about the decision-making process with
patients and caregivers during the inter-
vention? How did it go? What are you
opinions/prerogatives about/in advance
care planning?
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because perceived by patients as synonymous with ter-
minal care. The standardised passage will be,
“I propose you participate in a study in which you will
also be assisted by the staff of the palliative care unit.
Palliative care addresses all quality-of-life domains, and
we have been collaborating with this unit for several
years. However, there are no studies anywhere in the
world addressing the efficacy of this integrating model of
assistance. We would highly appreciate your participa-
tion in this study. Even if you decide not to participate
in the study, we will continue to assist you according to
the best standard of care.”
The PCI in the experimental arm
The initial assessment of patients enrolled in the experi-
mental arm will occur in the outpatient clinic or in the
ward as a consultation before the beginning of the last
active treatment. The Specialist Palliative Care Team
(SPCT) will follow each patient on a monthly basis in
the outpatient clinic or will provide consultations during
any hospital admission. SPCT and haematologists will
discuss active patient issues to assure a team approach
to the patient’s care. We will also consider family meet-
ings to improve communication among the patient, fam-
ily members and health professionals in which we will
share the patient’s status, goals of care and current
plans. Patients will be followed until death, referral to
PC community teams, refusal, or other reasons.
More specifically, the goals of integrating palliative
care earlier during the disease include the following:
– Specific attention to individual preferences for
information, including patient understanding/
awareness of the prognosis;
– improved physical and psychological symptom
detection and management;
– a continuous explanation of treatment goals and
support for patient decision-making;
– elements of advance care planning, progressively
introduced, according to the patients’ wishes;
– the possibility for relatives to meet the SPCT
professionals.
Integration with the Haematology teams will be
planned through the whole disease trajectory. Although
we do not have a specific structure for liaising with hae-
matologists, meetings and case conferences are per-
formed periodically with specific attention to critical
turning points such as periodical re-assessments, disease
progression, and major modification of the therapeutic
plan. Whenever possible, the two teams will have pre-
liminary discussions to reach a shared clinical proposal
for the patient to the maximum extent possible. All dis-
agreements will be negotiated within the meetings.
The standard PCI in the control arm
Patients randomised to the standard care arm can be
seen by the SPCT at the request of their haematologist
at any time. The intervention will not be standardised
but planned on the patients’ needs.
The date of SPCT interventions will also be recorded
for these patients.
Statistical methods
Statistical analysis
The feasibility of the early integrated PC intervention
will be assessed by estimating the proportion of haem-
atologic patients who agreed to participate in the inter-
vention and attended the first PC visit. We plan to
recruit 60 study participants. Feasibility will be achieved
if > 50% of patients remain in the programme 3months
after enrolment.
Secondary analyses include the quantitative evaluation
of changes in the score of the four questionnaires (POS,
ESAS, HADS and ECOG) within 6 months after
enrolment.
Descriptive summaries of the scores will be presented
by arm at each time point (baseline, 4, 8, 12, 16, 20 and
24 weeks from baseline). For each scale and for each
time point, changes from baseline will also be presented
with corresponding 95% confidence intervals. For each
scale, differences between arms will be estimated using
multi-level repeated-measures modelling adjusting for
scores at baseline.
Statistical analyses will be performed by the staff of
the Clinical Trials and Statistics Unit of the Azienda
USL-IRCCS. To this end, the SAS System or R will be
used according to availability and version in use.
Sample size estimation
The study was designed to randomise 60 patients. Feasi-
bility will be achieved if > 50% of patients remain in the
programme 3months after enrolment. It will be possible
to assess the feasibility of the experimental intervention
assuming a two-tailed type 1 error equal to 5% and a
statistical power equal to 80% given the following
assumptions:
1) planned statistical test: chi-squared test with 1 de-
gree of freedom;
2) p-value calculation mode: exact (because of the
small sample size);
3) alternative hypothesis: 75%;
4) allocation ratio: 1:1.
To reach the primary objective, the statistical test as
cited in point 1 will be used according to specifications
detailed in point 2; about the tested percentage, the
exact two-sided 95% confidence interval will be
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calculated according to the Clopper-Pearson approach.
Sample size was computed by using nQueryAdvisor,
procedure POT0x, version 7.0.
The qualitative analysis
The qualitative analysis will be performed as described
below. Recordings of the interviews will be transcribed
verbatim and then analysed using thematic analysis to
explore the content and context of responses [38, 39].
Each transcript will be independently labelled by two
researchers, who will reconcile differences in labelling.
Throughout an iterative process, they will inductively
identify a few subthemes. Finally, a third researcher will
revise both the transcripts and the preliminary thematic
analysis and regroup and rename some themes and sub-
themes with the objective of describing them by
highlighting commonalities and differences between the
perspectives of the three ‘actors’ involved. This revision
will be discussed and emended with the other re-
searchers involved in the qualitative analysis.
Blinding
Allocation status cannot be blinded for the participants
or trial personnel.
Ethics
Little evidence is available in the literature concerning
the beneficial effect of early palliative care in advanced
haematologic cancer patients. Furthermore, patients ran-
domised to standard treatment receive the same treat-
ment as they would have had if they had not entered
this trial, including SPCT consultation at the request of
their haematologist. These palliative interventions will
be reported in a case report file.
The protocol has been approved by the local ethics
committee (the Ethics Committee of the Area Vasta
Emilia Nord, No. 2018/0056350 of 18 May 2018) as
EPC-EMA1 and has been registered at www.clinicaltrials.
gov (NCT03743480).
Any protocol amendment will be submitted in ethics
committee and communicated to all the participants and
to clinicaltrials.gov
Discussion
This is the first trial assessing the early integration of
palliative care in patients with advanced haematological
malignancies. Other prospective studies have included
patients with acute leukaemia relapse [21] or patients
with high-risk acute myeloid leukaemia [40].
Palliative care is a holistic approach that aims to im-
prove quality of life in people with life-threatening ill-
ness and in their families [41]. A growing body of
literature has identified significant challenges in provid-
ing palliative care in a haematological setting [19, 42].
Barriers for palliative care integration include difficulty
in prognostication by haematologists, too little research
specifically on haematological cancer patients’ needs,
and misperceptions about palliative care as end-of-life
care [13–15].
Different haematologic diseases express different needs,
but there are basic palliative care needs in all hematologic
populations examined in many studies. The call for a new
model of integration between palliative care and haemato-
logic service is strong [16, 22]; some authors recommend
such care just from the beginning of an advanced disease
[17, 18], while other authors advocate its provision
according to the patients’ needs [19, 20].
Evidence supporting an effective model of integration
is missing. In clinical settings, palliative care is usually
offered by haematologists in the last days/weeks of life
or according to symptom burden, for example, in leu-
kaemia patients at high risk of relapse or who have
undergone transplant [10, 11, 23–26].In this trial, we will
test the feasibility of an integrated palliative care ap-
proach starting when the haematologist decides to
propose the last active treatment to the patient, accord-
ing to his/her clinical judgement. We decided to test this
criterion because it is very simple to understand, not
prognosis linked and, at the same time, able to intercept
a wide range of patients and needs. Moreover, the inclu-
sion criterion (judged by the hematologists) “the last ac-
tive treatment” will include incurable patients.
The hematologist specialists underestimate PC needs
and are reluctant to refer patients to a PC service. These
problems, in our opinion make this population more
homogenous than we could think according to the
haematologic diagnosis.
We therefore decide to include different onco-
hematologic diseases with different trajectories and char-
acteristics but with the same palliative care unmet need.
The feasibility of this approach requires that we enrol
at least 60 patients and that more than 50% of them be
followed by the palliative care team for at least 24 weeks.
Failure can derive from multiple reasons: a low rate of
recruitment because either the haematologists or the pa-
tients do not believe in the effectiveness of the interven-
tion; or a low proportion of patients followed for at least
24 weeks because the patients refuse to go on or because
the intervention starts too late in the course of the
disease.
Conversely, if the trial shows that this approach is
feasible – more than 50% of patients are followed by the
palliative care team for at least 24 weeks – the impact on
quality of life can be potentially relevant, considering
that the seminal Temel trial [43] was designed to assess
the impact of an integrated PCI at 12 weeks after rando-
misation.We establish 24 weeks as integrated assistance
length and, on the other hand, we include as inclusion
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criterion “life expectancy > one month”; is an attempt to
avoid enrollment of end-of-life hematologic patients
considering that literature showed an difficult in progno-
sis by hematologists.
The trial will include integrated qualitative data
analysis to deeply explore the strengths and weak-
nesses of the proposed approach from patients’ and
professionals’ point of view; this methodology can
give essential information on feasibility and accept-
ability, especially for vulnerable people, such as those
in palliative care, data that are difficult to obtain with
questionnaires or quantitative data assessment. More-
over, the qualitative approach can provide useful in-
formation for identifying the “active ingredients” of
the PCI.
Regardless, this study, independently of the results,
can provide useful information for modelling the most
effective integrated PCI in advanced haematological can-
cer patients.
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